Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Moderate Buy” by Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $53.40.

Several analysts recently weighed in on the company. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research note on Tuesday, February 10th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Needham & Company LLC restated a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 49,976 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the transaction, the executive vice president directly owned 71,770 shares in the company, valued at $2,900,225.70. The trade was a 41.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Dieter sold 13,976 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 1.85% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Collegium Pharmaceutical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after buying an additional 825 shares in the last quarter. Millennium Management LLC lifted its stake in Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after acquiring an additional 461,914 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Collegium Pharmaceutical by 7.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock valued at $2,120,000 after acquiring an additional 4,625 shares during the period. Jane Street Group LLC boosted its holdings in shares of Collegium Pharmaceutical by 218.7% during the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after acquiring an additional 90,255 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Collegium Pharmaceutical by 3.7% in the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after acquiring an additional 2,592 shares during the period.

Collegium Pharmaceutical Stock Down 0.3%

Shares of Collegium Pharmaceutical stock opened at $34.31 on Tuesday. Collegium Pharmaceutical has a 1 year low of $25.86 and a 1 year high of $50.79. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 20.06 and a beta of 0.77. The company has a 50-day moving average of $37.84 and a 200 day moving average of $41.55. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The business had revenue of $205.45 million during the quarter, compared to analysts’ expectations of $206.36 million. During the same quarter last year, the company posted $1.77 EPS. Collegium Pharmaceutical’s revenue for the quarter was up 12.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Collegium Pharmaceutical will post 6.51 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.